Payment overview · 2025
General Payments
$307.35
14 reported records · 9 companies
Healthcare provider profile · identity verified
David John Tucker, MD
Allopathic & Osteopathic Physicians|Family Medicine · GRAVETTE, AR · NPI 1023076619
Verified facts
What the public records show
CMS Open Payments records show David John Tucker, MD received $307.35 in general payments during 2025 across 14 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.18 | 26.7% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $52.28 | 17.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.78 | 14.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.14 | 10.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.03 | 7.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.58 | 6.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.73 | 6.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.71 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.92 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $307.35 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.18 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $52.28 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 886 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 659 | 113 |
| Gabapentin | Gabapentin | 559 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 551 | 106 |
| Potassium Chloride | Potassium Chloride | 493 | 78 |
| Lisinopril | Lisinopril | 485 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 444 | 76 |
| Metformin Hcl | Metformin Hcl | 369 | 65 |
| Omeprazole | Omeprazole | 362 | 67 |
| Tramadol Hcl | Tramadol Hcl | 352 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 345 | 61 |
| Furosemide | Furosemide | 341 | 72 |
| Oxycodone Hcl | Oxycodone Hcl | 340 | 50 |
| Losartan Potassium | Losartan Potassium | 338 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 338 | 61 |
| Trazodone Hcl | Trazodone Hcl | 336 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 335 | 66 |
| Eliquis | Apixaban | 316 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 276 | 74 |
| Glipizide | Glipizide | 262 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 258 | 47 |
| Pregabalin | Pregabalin | 255 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 246 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 246 | 52 |
| Alprazolam | Alprazolam | 240 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 232 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 223 | 34 |
| Carvedilol | Carvedilol | 222 | 37 |
| Sertraline Hcl | Sertraline Hcl | 222 | 35 |
| Meloxicam | Meloxicam | 204 | 35 |
| Xarelto | Rivaroxaban | 202 | 18 |
| Celecoxib | Celecoxib | 196 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 37 |
| Gemtesa | Vibegron | 188 | 13 |
| Cephalexin | Cephalexin | 173 | 83 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 166 | 39 |
| Allopurinol | Allopurinol | 162 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 154 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 150 | 32 |
| Ozempic | Semaglutide | 129 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 25 |
| Prednisone | Prednisone | 118 | 56 |
| Sucralfate | Sucralfate | 116 | 25 |
| Montelukast Sodium | Montelukast Sodium | 115 | 18 |
| Estradiol | Estradiol | 112 | 26 |
| Lorazepam | Lorazepam | 111 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 106 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 105 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 38 |
| Famotidine | Famotidine | 102 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 98 | 11 |
| Fluconazole | Fluconazole | 95 | 34 |
| Mirtazapine | Mirtazapine | 95 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 37 |
| Clonazepam | Clonazepam | 91 | 22 |
| Spironolactone | Spironolactone | 91 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 48 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 89 | 17 |
| Meclizine Hcl | Meclizine Hcl | 88 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 12 |
| Atenolol | Atenolol | 85 | 17 |
| Simvastatin | Simvastatin | 84 | 18 |
| Ibuprofen | Ibuprofen | 79 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 78 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 50 |
| Finasteride | Finasteride | 76 | suppressed |
| Ezetimibe | Ezetimibe | 73 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 72 | 19 |
| Diazepam | Diazepam | 71 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 14 |
| Levofloxacin | Levofloxacin | 70 | 46 |
| Methocarbamol | Methocarbamol | 69 | 17 |
| Clonidine Hcl | Clonidine Hcl | 67 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 14 |
| Memantine Hcl | Memantine Hcl | 65 | 13 |
| Donepezil Hcl | Donepezil Hcl | 63 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 15 |
| Nystatin | Nystatin | 63 | 27 |
| Albuterol Sulfate | Albuterol Sulfate | 62 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 33 |
| Metoclopramide Hcl | Metoclopramide Hcl | 57 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 55 | 12 |
| Fentanyl | Fentanyl | 55 | suppressed |
| Novolog | Insulin Aspart | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 13 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 27 |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Valsartan | Valsartan | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Ondansetron Odt | Ondansetron | 49 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 47 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | 36 |
| Doxepin Hcl | Doxepin Hcl | 46 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 46 | suppressed |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 41 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Digoxin | Digoxin | 40 | 11 |
| Linzess | Linaclotide | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 22 |
| Metolazone | Metolazone | 37 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 37 | suppressed |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Sulindac | Sulindac | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 12 |
| Naproxen | Naproxen | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 17 |
| Baclofen | Baclofen | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Pentoxifylline | Pentoxifylline | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 24 |
| Topiramate | Topiramate | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 15 |
| Mupirocin | Mupirocin | 24 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | 11 |
| Cefdinir | Cefdinir | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Menest | Estrogens,esterified | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $307.35 · 14 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AUSTEDO XR, CAPLYTA, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, INSPIRE, JOURNAVX, MOUNJARO, OTEZLA, REPATHA, YUPELRI, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error